Douglas VanOort, the company's Chairman and CEO, commented, "Development of this software is a result of our commitment to offer innovative solutions and uncompromising quality for cancer testing. This innovation resulted from our licensing agreement with Health Discovery Corp, which provides NeoGenomics the exclusive worldwide rights to use SVM technology for all types of laboratory developed tests in hematopoietic and solid tumor cancers. We expect SVM technology will help us to automate certain manual testing processes, provide more accurate results for those tests that were previously dependent on subjective interpretations, and increase the productivity of our lab operations. To our knowledge, we are the first laboratory in the world to use SVM technology to assist in reading and interpreting ALK FISH data."Dr. Maher Albitar, the Company's Chief Medical Officer and Director of Research and Development, commented, "The science around using pattern recognition and computer-aided algorithms has improved significantly in the past few years. Our use of algorithms to interpret FISH digital data is just one step in a series of planned activities to adapt the SVM technology to cancer genetics testing. We believe these types of algorithms will be instrumental in helping to answer complex clinical questions and reducing the dependence on subjective interpretations." About NeoGenomics, Inc. NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com. About Health Discovery Corporation (OTCBB: HDVY) Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques, such as Support Vector Machine (SVM) technology, to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward Looking Statements Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.